|
|||||||||||||||||||||||||||
Clinical TrialsGenetic Immunity's DermaVir Patch is a potential first-in-class antiviral nanomedicine designed to inhibit viral replication by cytotoxic killing of HIV-infected cells. Currently, there are no approved immune magnifying nanomedicinces on the market to treat HIV/AIDS. The following DermaVir trials were started: Phase I (GIHU004)A PHASE I STUDY TO EVALUATE THE TOLERABILITY AND SAFETY OF A LC002, A DERMAVIR VACCINE, IN HIV-1-INFECTED SUBJECTS CURRENTLY UNDER TREATMENT WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
![]() To read Study Synopsis click here... Phase I/II (ACTG 5176)A PHASE I/II, RANDOMIZED, DOUBLE-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF LC002, A DERMAVIR VACCINE, IN HIV-1-INFECTED SUBJECTS CURRENTLY UNDER TREATMENT WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
![]() To read Study Synopsis click here... Phase II (DermHIVImm)ACTIVE IMMUNOTHERAPY AGAINST HIV DURING HIGHLY ACTIVE ANTI-RETROVIRAL THERAPY FOLLOWED BY REPEATED TREATMENT INTERRUPTIONS, VAC 09. A PHASE I
![]() To read Study Synopsis click here... Phase II (GIEU006)PHASE II, RANDOMIZED, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND ANTIRETROVIRAL ACTIVITY OF DERMAVIR (LC002) PATCH IN TREATMENT-NAÏVE HIV-1-INFECTED PATIENTS
![]() To read Study Synopsis click here... Phase I/II IMPAACT-P1049 (in preparation)A PHASE I/II STUDY OF THE SAFETY, TOLERABILITY AND IMMUNOGENECITY OF A TOPICAL THERAPEUTIC DNA DENRITIC CELL VACCINE (DERMAVIR PATCH) IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS WITH HIV-1 INFECTION ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART).
|
|
||||||||||||||||||||||||||
| Site Map | Last Update: January 3, 2009 |